Table 2 Relative fold change in tumor bioluminescence over the course of drug treatment

From: Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles

Cell line

Average fold increase in tumor bioluminescence at day 7 of treatment

Free drug

PEG-NP drug

Tf-NP drug

Veh

JQ1

TMZ

JQ1 + TMZ

Veh

JQ1

TMZ

JQ1 + TMZ

Veh

JQ1

TMZ

JQ1 + TMZ

U87MG

341 ± 64

280 ± 91

96 ± 27

18 ± 6

430 ± 27

122 ± 7

96 ± 2

21 ± 1

354 ± 26

53 ± 10

7 ± 1

0.9 ± 0.3

GL261

77 ± 16

44 ± 5

25 ± 6

3 ± 2

88 ± 1.8

42 ± 6

25 ± 7

4 ± 0.5

74 ± 5

14 ± 5

18 ± 3

0.7 ± 0.1

  1. Average fold change (±S.D.) in tumor bioluminescence in different treatment arms at day 7 of treatment
Back to article page